Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes.
Exendin-4 (Ex-4) is a Glucagon-like peptide 1 (GLP-1) receptor agonist approved for the treatment of Type 2 Diabetes (T2DM), which requires daily subcutaneous administration. In T2DM patients, GLP-1 administration is reported to reduce glycaemia and HbA1c in association with a modest, but significan...
Guardado en:
Autores principales: | Giovanni Di Pasquale, Ilaria Dicembrini, Laura Raimondi, Claudio Pagano, Josephine M Egan, Andrea Cozzi, Lorenzo Cinci, Andrea Loreto, Maria E Manni, Silvia Berretti, Annamaria Morelli, Changyu Zheng, Drew G Michael, Mario Maggi, Roberto Vettor, John A Chiorini, Edoardo Mannucci, Carlo M Rotella |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b5a58b6ba4de46ae91ab1ee5fd254e6b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Exendin-4 Exhibits Enhanced Anti-tumor Effects in Diabetic Mice
por: Lan He, et al.
Publicado: (2017) -
Mitochondria-targeted antioxidant protects against irradiation-induced salivary gland hypofunction
por: Xibao Liu, et al.
Publicado: (2021) -
Non-invasive in vivo determination of viable islet graft volume by 111In-exendin-3
por: Wael A. Eter, et al.
Publicado: (2017) -
Albumin-binding tag derived Exendin-4 analogue for treating hyperglycemia and diabetic complications
por: Shujuan Xu, et al.
Publicado: (2021) -
Author Correction: Mitochondria-targeted antioxidant protects against irradiation-induced salivary gland hypofunction
por: Xibao Liu, et al.
Publicado: (2021)